NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Thermo Fisher Scientific' stock, noting the firm's increased scale as a result of its purchase of Life Technologies, as well as improving end markets.

The investment bank lifted Thermo Fisher's shares to a Buy rating from a previous Neutral rating and increased the 12-month price target on its stock to $153 from $114.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.